TB-500 (Thymosin Beta-4): Mechanism and Scientific Evidence
Guide to TB-500: active fragment of Thymosin Beta-4, mechanism of action on G-actin, cell motility studies and association with BPC-157 described in literature.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino acid protein with high prevalence in injured tissues. Studies demonstrate it promotes actin polymerization, facilitating cell migration and angiogenesis. It also modulates inflammatory pathways via NFκB downregulation and matrix metalloproteinase (MMP) upregulation.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓Acceleration of tendon and muscle healing in animal models
- ✓Cardiac regeneration studies: stem cell mobilization in infarct models
- ✓Research in cutaneous wound healing and burns
- ✓Neuroprotective investigations in stroke and spinal cord injury models
- ✓Studies in ocular inflammation and corneal regeneration
Relevant Studies
Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization
2011 · PMID: 21241358
Thymosin beta-4 accelerates wound healing
1999 · PMID: 10681504
Thymosin Beta-4 mediated PKC activation is essential to initiate the cardiac stem cell survival and organ rescue
2010 · PMID: 20056941
Premium
✓ DesbloqueadoProtocols Described in the Literature
TB-500 clinical studies were conducted mainly in animal models (equine and rodents), with some human venous ulcer trials. Protocols described in the literature distinguish initial saturation phases (higher frequency) and maintenance phases (reduced frequency). Combination with BPC-157 is frequently referenced in musculoskeletal recovery contexts.
Dose Ranges Observed in Studies
- ◆Equine studies document 5–10 mg per administration in tendon injuries
- ◆Human extrapolations: ranges of 2–5 mg described in exploratory clinical use literature
- ◆Loading phase: studies describe more frequent administrations in the first 4–6 weeks
- ◆Maintenance phase: reduced frequency described after clinical stabilization
Effects Timeline (Literature)
Healing studies demonstrate onset of angiogenic response in 3–7 days. Histological improvement in tendon models observed from 14 days. Complete functional recovery documented in 4–8 weeks depending on injury extent. Cardiac studies report epicardial stem cell mobilization in the first 72h.
Documented Associations
- ↗BPC-157: most documented combination for musculoskeletal recovery, with biological plausibility from mechanistic complementarity
- ↗GHK-Cu: plausibility for soft tissue regeneration and angiogenesis
- ↗Ipamorelin/CJC-1295: optimization context for recovery and body composition
Monitoring Described in Studies
- ⊕Clinical and imaging evaluation of the injury: standard in efficacy studies
- ⊕Tissue remodeling markers: types I and III collagen in histological studies
- ⊕Echocardiography: assessed in cardiac post-infarct regeneration studies
Clinical Observations from Studies
- ℹOnly published human clinical trial: venous ulcer study with positive healing results
- ℹEquine studies are the most robust musculoskeletal efficacy data basis available
- ℹHigh molecular stability: resistance to proteolytic degradation described in stability studies
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
What is TB-500?▼
TB-500 is the synthetic active fragment of Thymosin Beta-4 (Tβ4), a 43-amino acid protein that binds G-actin and regulates actin polymerization. Studies describe actions in cell migration and tissue response.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.